Mitoxantrona Pharmis (Mitoxantrone)

Mitoxantrone intercalates into DNA and stabilises the topoisomerase II‑DNA complex, preventing the enzyme from resealing DNA strands. This creates double‑strand breaks, triggers cell‑cycle arrest and activates apoptotic pathways, leading to selective death of rapidly dividing tumour cells.

The dose of mitoxantrone is individualized by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, renal function and prior therapies. Only a qualified healthcare professional should determine the dosing schedule.

The safety of mitoxantrone in pregnancy and lactation has not been established. It is generally avoided unless the potential benefit to the mother outweighs the possible risk to the fetus or infant, and the decision should be made by a specialist.

To request Mitoxantrona Pharmis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Mitoxantrone belongs to the anthracenedione class and differs from anthracyclines such as doxorubicin by having a distinct DNA‑intercalating profile and a lower incidence of certain cardiac toxicities. However, it shares risks like myelosuppression and requires careful monitoring, making the choice of agent dependent on the tumour type and patient tolerance.

Mitoxantrona Pharmis must be stored at 2‑8 °C in a refrigerator, protected from light. The vial should remain in its original packaging, must not be frozen or shaken, and should be used within the stability period indicated by the manufacturer.

The product is supplied as an injectable solution for intravenous infusion. Administration is performed by trained healthcare professionals in a clinical setting, typically over a defined period according to the prescribed chemotherapy protocol.

Serious risks include cardiotoxicity leading to reduced heart function, secondary malignancies such as therapy‑related leukemia, and severe infections due to profound neutropenia. Patients should be monitored closely for cardiac symptoms, blood counts and signs of infection throughout treatment.

Mitoxantrona Pharmis is contraindicated in patients with known hypersensitivity to mitoxantrone or any component of the formulation, in those with uncontrolled cardiac disease, and in pregnant or nursing women unless the therapeutic benefit justifies the potential risk.